The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumResearch - Affimed jumped yesterday after reporting unexpected activity of AFM24+atezolizumab in EGFR+ solid tumors. The initial results from the Phase 1 dose escalation study showed that … Continue Reading
PremiumInsights - Affimed announced an early peek at updated AFM13+NK data that will be presented at ASH conference on December 10, 2022. The data was strong. Importantly, … Continue Reading
PremiumInsights - Medicenna (MDNA) confirmed the partial response (PR) that the Company previously reported from their imaging scan in July. The patient with the confirmed PR was … Continue Reading
PremiumInsights - Astria (ATXS) is up 135% since we bought a position in early August under $4/share. The Company initiated the Phase 1 program for their STAR-0215 … Continue Reading
PremiumInsights - We bought Milestone Pharma (MIST) just over a month ago under $7/share to play the topline Phase 3 data readout on track for mid-2H 2022. … Continue Reading
PremiumInsights - Affimed gave a Q2 2022 business update which was mixed. Their second half is expected to have a few catalysts, but the company also announced … Continue Reading
PremiumResearch - This morning Medicenna (MDNA) announced the pricing of a $20M financing. 13.33M shares were sold at $1.50/share and came with an additional 13.33M 5-year warrants at $1.85/share. … Continue Reading
Premium
